HOWL Q2 2024 Earnings — Werewolf Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HOWLWerewolf Therapeutics, Inc.

$35M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-85.9% YoY

Gross Profit

$689,00060.3% margin

Operating Income

-$19M-1658.8% margin

Net Income

-$17M-1509.1% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+54.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$154M

Total Liabilities

$50M

Stockholders' Equity

$104M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$8M	-85.9%
Gross Profit	$689,000	$8M	-91.5%
Operating Income	-$19M	-$6M	-212.5%
Net Income	-$17M	-$5M	-238.3%